Experion’s Cholesterol Drug Looks Great in Phase III, but Faces Tough Market

Esperion, based in Ann Arbor, Mich., announced results from its Phase III Study 2 of bempedoic acid at the American College of Cardiology (ACC) annual meeting. The drug is being developed as a complementary, cost-effective, once-daily, oral cholesterol-lowering therapy.